Ryuichi Harada1, Shozo Furumoto2, Tetsuro Tago2, Katsutoshi Furukawa, Aiko Ishiki3, Naoki Tomita3, Ren Iwata2, Manabu Tashiro2, Hiroyuki Arai3, Kazuhiko Yanai2,4, Yukitsuka Kudo1,2, Nobuyuki Okamura5,6,7. 1. Division of Neuro-imaging, Institute of Development, Aging and Cancer, Tohoku University, Sendai, 980-8575, Japan. 2. Cyclotron and Radioisotope Center, Tohoku University, Sendai, 980-8578, Japan. 3. Department of Geriatrics and Gerontology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, 980-8575, Japan. 4. Department of Pharmacology, Tohoku University School of Medicine, Sendai, 980-8575, Japan. 5. Division of Neuro-imaging, Institute of Development, Aging and Cancer, Tohoku University, Sendai, 980-8575, Japan. nookamura@med.tohoku.ac.jp. 6. Cyclotron and Radioisotope Center, Tohoku University, Sendai, 980-8578, Japan. nookamura@med.tohoku.ac.jp. 7. Division of Pharmacology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, 981-8558, Japan. nookamura@med.tohoku.ac.jp.
Abstract
PURPOSE: 18F-THK5351 is a novel radiotracer developed for in vivo imaging of tau pathology in the brain. For the quantitative assessment of tau deposits in the brain, it is important that the radioactive metabolite does not enter the brain and that it does not bind to tau fibrils. The purpose of the study was to identify a radiolabeled metabolite of 18F-THK5351 in blood samples from human subjects and to characterize its pharmacological properties. METHODS: Venous blood samples were collected from three human subjects after injection of 18F-THK5351 and the plasma metabolite was measured by high performance thin layer chromatography. In addition, mass spectrometry analysis and enzymatic assays were used to identify this metabolite. Mice were used to investigate the blood-brain barrier permeability of the radioactive metabolite. Furthermore, the binding ability of the metabolite to tau aggregates was evaluated using autoradiography and binding assays using human brain samples. RESULTS: About 13 % of the unmetabolized radiotracer was detectable in human plasma at 60 min following the injection of 18F-THK5351. The isolated radiometabolite of 18F-THK5351 was the sulphoconjugate of THK5351. This metabolite could be produced in vitro by incubating THK5351 with liver but not brain homogenates. The metabolite did not penetrate the blood-brain barrier in mice, and exhibited little binding to tau protein aggregates in post-mortem human brain samples. CONCLUSIONS: These results suggest that the sole metabolite detectable in plasma seems to be generated outside the brain and does not cross into the brain, which does not affect quantitative analysis of PET images.
PURPOSE: 18F-THK5351 is a novel radiotracer developed for in vivo imaging of tau pathology in the brain. For the quantitative assessment of tau deposits in the brain, it is important that the radioactive metabolite does not enter the brain and that it does not bind to tau fibrils. The purpose of the study was to identify a radiolabeled metabolite of 18F-THK5351 in blood samples from human subjects and to characterize its pharmacological properties. METHODS: Venous blood samples were collected from three human subjects after injection of 18F-THK5351 and the plasma metabolite was measured by high performance thin layer chromatography. In addition, mass spectrometry analysis and enzymatic assays were used to identify this metabolite. Mice were used to investigate the blood-brain barrier permeability of the radioactive metabolite. Furthermore, the binding ability of the metabolite to tau aggregates was evaluated using autoradiography and binding assays using human brain samples. RESULTS: About 13 % of the unmetabolized radiotracer was detectable in human plasma at 60 min following the injection of 18F-THK5351. The isolated radiometabolite of 18F-THK5351 was the sulphoconjugate of THK5351. This metabolite could be produced in vitro by incubating THK5351 with liver but not brain homogenates. The metabolite did not penetrate the blood-brain barrier in mice, and exhibited little binding to tau protein aggregates in post-mortem human brain samples. CONCLUSIONS: These results suggest that the sole metabolite detectable in plasma seems to be generated outside the brain and does not cross into the brain, which does not affect quantitative analysis of PET images.
Entities:
Keywords:
Alzheimer’s disease; PET; Radiolabeled metabolite; Tau
Authors: David T Chien; Shadfar Bahri; A Katrin Szardenings; Joseph C Walsh; Fanrong Mu; Min-Ying Su; William R Shankle; Arkadij Elizarov; Hartmuth C Kolb Journal: J Alzheimers Dis Date: 2013 Impact factor: 4.472
Authors: Chun-Fang Xia; Janna Arteaga; Gang Chen; Umesh Gangadharmath; Luis F Gomez; Dhanalakshmi Kasi; Chung Lam; Qianwa Liang; Changhui Liu; Vani P Mocharla; Fanrong Mu; Anjana Sinha; Helen Su; A Katrin Szardenings; Joseph C Walsh; Eric Wang; Chul Yu; Wei Zhang; Tieming Zhao; Hartmuth C Kolb Journal: Alzheimers Dement Date: 2013-02-12 Impact factor: 21.566
Authors: Gert Luurtsema; Robert C Schuit; Kevin Takkenkamp; Mark Lubberink; N Harry Hendrikse; Albert D Windhorst; Carla F M Molthoff; Nelleke Tolboom; Bart N M van Berckel; Adriaan A Lammertsma Journal: Nucl Med Biol Date: 2008-11 Impact factor: 2.408
Authors: David T Chien; A Katrin Szardenings; Shadfar Bahri; Joseph C Walsh; Fanrong Mu; Chunfang Xia; William R Shankle; Alan J Lerner; Min-Ying Su; Arkadij Elizarov; Hartmuth C Kolb Journal: J Alzheimers Dis Date: 2014 Impact factor: 4.472
Authors: Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici Journal: Acta Neuropathol Date: 2006-08-12 Impact factor: 17.088
Authors: Tobey J Betthauser; Paul A Ellison; Dhanabalan Murali; Patrick J Lao; Todd E Barnhart; Shozo Furumoto; Nobuyuki Okamura; Sterling C Johnson; Jonathan W Engle; Robert J Nickles; Bradley T Christian Journal: Appl Radiat Isot Date: 2017-10-04 Impact factor: 1.513
Authors: Cinthya Aguero; Maeva Dhaynaut; Marc D Normandin; Ana C Amaral; Nicolas J Guehl; Ramesh Neelamegam; Marta Marquie; Keith A Johnson; Georges El Fakhri; Matthew P Frosch; Teresa Gomez-Isla Journal: Acta Neuropathol Commun Date: 2019-03-11 Impact factor: 7.801
Authors: Yi Li; Mony J de Leon; Henry Rusinek; Tracy Butler; Lidia Glodzik; Elizabeth Pirraglia; John Babich; P David Mozley; Sadek Nehmeh; Silky Pahlajani; Xiuyuan Wang; Emily B Tanzi; Liangdong Zhou; Sara Strauss; Roxana O Carare; Neil Theise; Nobuyuki Okamura Journal: Fluids Barriers CNS Date: 2022-03-14
Authors: Kiran Kumar Solingapuram Sai; Xiaofei Chen; Zhe Li; Caigang Zhu; Kirtikar Shukla; Tom E Forshaw; Hanzhi Wu; Stephen A Vance; Buddhika Liyana Pathirannahel; Megan Madonna; Mark W Dewhirst; Allen W Tsang; Leslie B Poole; Nimmi Ramanujam; S Bruce King; Cristina M Furdui Journal: Redox Biol Date: 2021-12-18 Impact factor: 11.799